Pre-Market Stock Notes (JAN 9, 2007)

(AA) Alcoa reports after close and is expecting $0.65 EPS on sales of roughly $7.6 Billion.
(AAPL) Apple is up 1% ahead of macWorld on expected Apple Phone.
(ACAS) American Capital Strategies priced 6.3M shares at$45.83.
(AGIX) Atherogenics refined the timing on its ARISE clinical trial.
(BABY) Natus lowered guidance to lower-end of range.
(CELG) Celgene trading down 5% on slightly lowered guidance.
(CRDN) Ceradyne raised revenues to $178M for last quarter preliminary numbers vs $173M (e).
(EMMS) Emmis $0.02 EPS vs $0.01e.
(GAP) Great Atlantic Pacific & Tea reported narrower losses and looks actually profitable.
(GBX) Greebriar $0.12 EPS vs $0.12e.
(GE) GE is finally selling off its GE Plastics unit and will seek bids in an expected $10B sale.
(GILD) Gilead up on Cramer comments ahead of JPMorgan Biotech Conference.
(HELE) Helen of Troy down 12%after missing earnings expectations.
(HOKU) Hoku is planning a new $220M polysilicon plant construction.
(IAR) Idearc filed to sell 2.5M shares of common stock.
(JNPR) Juniper named Stephen Elop as its Chief Operating Officer, former President/CEO of Macromedia.
(KVHI) KVH Industries lowered guidance.
(MENT) Mentor Graphics raised guidance; stock rose 2%.
(NWY) New York & Co put EPS at lower-end of range.
(OPTM) Optium is #1 overlooked IPO from 2006.
(OSIR) Osiris Therapeutics received FDA Fast Track designation on its stem cell treatment for Crohn’s Disease and will proceed to Phase III trials.
(PFGC) Performance Foods sees EPS $0.17-0.20 vs 0.19e.
(S) Sprint fell 8% after-hours on lowered guidance and 5,000 job cuts.
(SVU) Supervalu earnings were a tad light to street but within expectations and guidance of company.
(TMO) Thermo Fisher positive from Cramer ahead of JPMorgan Biotech Conference.
(TWB) Tween Brands lowered guidance.
(WSM) William Sonoma holiday sales (s-s-s) +1.1%; sees EPS $1.03-1.09 vs $1.03e.

by Jon C. Ogg
January 9, 2007